Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-7wlv9 Total loading time: 1.389 Render date: 2022-05-17T02:22:05.841Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Chapter 21 - Specific Treatments for Major Acute Ischemic Stroke

from Section 4 - Treatment of Transient Ischemic Attack and Stroke

Published online by Cambridge University Press:  01 August 2018

Gary K. K. Lau
Affiliation:
University of Oxford
Sarah T. Pendlebury
Affiliation:
University of Oxford
Peter M. Rothwell
Affiliation:
University of Oxford
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Transient Ischemic Attack and Stroke
Diagnosis, Investigation and Treatment
, pp. 307 - 327
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albers, GW, von Kummer, R, Truelsen, T et al. (2015) Safety and efficacy of desmoteplase given 3–9 h after ischemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): A double-blind, randomized, placebo-controlled phase 3 trial. Lancet Neurology 14:575584CrossRefGoogle ScholarPubMed
Albers, GW, Marks, MP, Kemp, S et al. (2018). Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. New England Journal of Medicine 378:708718CrossRefGoogle ScholarPubMed
Anderson, CS, Robinson, T, Lindley, RI et al. (2016). Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. New England Journal of Medicine 374:23132323CrossRefGoogle ScholarPubMed
Berge, E (2007). Heparin for acute ischemic stroke: A never-ending story? Lancet Neurology 6:381382CrossRefGoogle ScholarPubMed
Berge, E, Cohen, G, Roaldsen, MB et al. (2016). Effects of alteplase on survival after ischemic stroke (IST-3): 3 year follow-up of a randomized, controlled, open-label trial. Lancet Neurology 15:10281034CrossRefGoogle Scholar
Berkhemer, OA, Fransen, PS, Beumer, D et al. (2015). A randomized trial of intraarterial treatment for acute ischemic stroke. New England Journal of Medicine 372:1120CrossRefGoogle ScholarPubMed
Bernard, SAGT, Buist, MD, Jones, BM et al. (2002). Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. New England Journal of Medicine 346:557563CrossRefGoogle ScholarPubMed
Bhatia, R, Hill, MD, Shobha, N et al. (2010). Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: Real-world experience and a call for action. Stroke 41:22542258CrossRefGoogle Scholar
Broderick, JP, Palesch, YY, Demchuck, AM et al. (2013). Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. New England Journal of Medicine. 368:893903CrossRefGoogle ScholarPubMed
Brott, TG, Haley, EC Jr., Levy, DE et al. (1992). Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23:632640CrossRefGoogle ScholarPubMed
Campbell, BC, Mitchell, MJ, Kleinig, TJ et al. (2015). Endovascular therapy for ischemic stroke with perfusion-imaging selection. New England Journal of Medicine 372:10091018CrossRefGoogle ScholarPubMed
Chinese Acute Stroke Trial (CAST) Collaborative Group (1997). CAST: Randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischemic stroke. Lancet 349:16411649CrossRef
Ciccone, A, Valvassori, L, Nichelatti, M et al. (2013). Endovascular treatment for acute ischemic stroke. New England Journal of Medicine 368:904913CrossRefGoogle ScholarPubMed
Clark, WM, Wissman, S, Albers, GW et al. (1999). Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for acute Noninterventional Therapy in Ischemic Stroke. JAMA 282:20192026CrossRefGoogle ScholarPubMed
Collen, D. (1987) Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. Journal of Cellular Biochemistry 33:7786CrossRefGoogle ScholarPubMed
Connolly, SJ, Milling, TJ Jr., Eikelboom, JW et al. (2016). Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. New England Journal of Medicine 375:11311141CrossRefGoogle ScholarPubMed
Davis, SM, Donnan, GA, Parsons, MW et al. (2008) Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomized trial. Lancet Neurology 7:299309CrossRefGoogle Scholar
del Zoppo, GJ, Higashida, RT, Furlan, AJ et al. (1998). PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators Prolyse in Acute Cerebral Thromboembolism. Stroke 29:411CrossRefGoogle ScholarPubMed
Demaerschalk, BM, Kleindorfer, DO, Adeoye, OM et al. (2016). Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 47:581641CrossRefGoogle ScholarPubMed
Emberson, J, Lee, KR, Lyden, P et al. (2014). Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischemic stroke: A meta-analysis of individual patient data from randomized trials. Lancet 384:19291935CrossRefGoogle Scholar
Fletcher, AP, Alkjaersig, N, Lewis, M et al. (1976). A pilot study of urokinase therapy in cerebral infarction. Stroke 7:135142CrossRefGoogle ScholarPubMed
Furlan, A, Higashida, R, Wechsler, L et al. (1999). Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Journal of the American Medical Association 282:20032011CrossRefGoogle ScholarPubMed
Furlan, AJ, Eyding, D, Albers, GW et al. (2006). Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37:12271231CrossRefGoogle ScholarPubMed
Goyal, M, Demchuk, AM, Menon, BK et al. (2015). Randomized assessment of rapid endovascular treatment of ischemic stroke. New England Journal of Medicine 372:10191030CrossRefGoogle ScholarPubMed
Goyal, M, Menon, BK, van Zwam, WH et al. (2016). Endovascular thrombectomy after large-vessel ischemic stroke: A meta-analysis of individual patient data from five randomized trials. Lancet 387:17231731CrossRefGoogle Scholar
Gupta, R, Horev, A, Nguyen, T et al. (2013). Higher volume endovascular stroke centers have faster times to treatment, higher reperfusion rates and higher rates of good clinical outcomes. Journal of NeuroInterventional Surgery 5:294297CrossRefGoogle ScholarPubMed
Hacke, W, Kaste, M, Fieschi, C et al. (1995). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Coorperative Acute Stroke Study (ECASS). JAMA 274:10171025CrossRefGoogle Scholar
Hacke, W, Kaste, M, Fieschi, C et al. (1998). Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European–Australasian Acute Stroke Study Investigators. Lancet 352:12451251CrossRefGoogle ScholarPubMed
Hacke, W, Albers, G, Al-Rawi, Y et al. (2005). The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36:6673CrossRefGoogle ScholarPubMed
Haley, EC Jr., Levy, DE, Brott, TG et al. (1992). Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 23:641645CrossRefGoogle ScholarPubMed
Hankey, GJ, Norrving, B, Hacke, W et al. (2014). Management of acute stroke in patients taking novel oral anticoagulants. International Journal of Stroke 9:627632CrossRefGoogle ScholarPubMed
Hemmen, TM, Lyden, PD (2007). Induced hypothermia for acute stroke. Stroke 38:794799CrossRefGoogle ScholarPubMed
Hypothermia After Cardiac Arrest Study Group (2002). Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. New England Journal of Medicine 346:549556CrossRef
International Stroke Trial Collaborative Group (1997). The International Stroke Trial (IST): A randomised trial of aspirin subcutaneous heparin both or neither among 19435 patients with acute ischemic stroke. Lancet 349:15691581CrossRef
IST-3 Collaborative Group (2012). The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischemic stroke [the third International Stroke Trial (IST-3)]: A randomized controlled trial. Lancet 379:23522363CrossRef
IST-3 Collaborative Group (2015). Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischemic stroke in the third International Stroke Trial (IST-3): Secondary analysis of a randomized controlled trial. Lancet Neurology 14:485496CrossRef
Jauch, EC, Saver, JL, Adams, HP et al. (2013). Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870947CrossRefGoogle ScholarPubMed
Jovin, TG, Chamorro, A, Cobo, E et al. (2015). Thrombectomy within 8 hours after symptom onset in ischemic stroke. New England Journal of Medicine. 372:22962306CrossRefGoogle ScholarPubMed
Kidwell, CS, Jahan, R, Gornbein, J et al. (2013). A trial of imaging selection and endovascular treatment for ischemic stroke. New England Journal of Medicine 368:914923CrossRefGoogle ScholarPubMed
Krieger, DW, Yenari, MA (2004). Therapeutic hypothermia for acute ischemic stroke: What do laboratory studies teach us? Stroke 35:14821489CrossRefGoogle ScholarPubMed
Lyden, PD, Madden, KP, Clark, WM et al. (1990). Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits. Stroke 21:15891593CrossRefGoogle ScholarPubMed
Ma, QF, Chu, CB, Song, HQ (2015). Intravenous versus intra-arterial thrombolysis in ischemic stroke: A systematic review and meta-analysis. PLoS One 10:e0116120CrossRefGoogle ScholarPubMed
Menon, BK, Saver, JL, Prabhakaran, S et al. (2012). Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 43:22932299CrossRefGoogle ScholarPubMed
Meyer, JS, Gilroy, J, Barnhart, MI et al. (1963). Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 13:927937CrossRefGoogle ScholarPubMed
Muir, KW (2001). Magnesium for neuroprotection in ischemic stroke: Rationale for use and evidence of effectiveness. CNS Drugs 15:921930CrossRefGoogle Scholar
Multicenter Acute Stroke Trial – Europe Study Group (1996). Thrombolytic therapy with streptokinase in acute ischemic stroke. New England Journal of Medicine 335:145150CrossRef
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine 333:15811588CrossRef
Nogueira, RG, Lutsep, HL, Gupta, R et al. (2012). Trevo versus Merci retrievers for thrombectomy revascularization of large vessel occlusion in acute ischemic stroke (TREVO 2): A randomized trial. Lancet 38:12311240CrossRefGoogle Scholar
Nogueira, RG, Jadhav, AP, Haussen, DC et al. (2018). Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. New England Journal of Medicine 378:1121CrossRefGoogle ScholarPubMed
O’Donnell, MJ, Berge, E, Sandset, PM (2006). Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? Stroke 37:452455CrossRefGoogle ScholarPubMed
Parsons, M, Spratt, N, Bivard, A et al. (2012). A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine 366:10991107CrossRefGoogle ScholarPubMed
Pierot, L, Soize, S, Benaissa, A et al. (2015). Techniques for endovascular treatment of acute ischemic stroke: From intra-arterial fibrinolytics to stent-retrievers. Stroke 46:909914CrossRefGoogle ScholarPubMed
Pollack, CV Jr., Reilly, PA, Eikelboom, J et al. (2015). Idarucizumab for dabigatran reversal. New England Journal of Medicine 373:511520CrossRefGoogle ScholarPubMed
Powers, WJ, Derdeyn, CP, Biller, J et al. (2015). 2015 American Heart Association/American Stroke Association focused updated of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 46:30203035CrossRefGoogle Scholar
Powers, WJ, Rabinstein, AA, Ackerson, T et al. (2018). Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49:e46e110CrossRefGoogle ScholarPubMed
Rothwell, PM, Algra, A, Chen, Z et al. (2016). Effects of aspirin on risk of severity of early recurrent stroke after transient ischemic attack and ischemic stroke: Time-course analysis of randomized trials. Lancet 388:365375CrossRefGoogle Scholar
Sandercock, P, Gubitz, G, Foley, P et al. (2003). Antiplatelet therapy for acute ischemic stroke. Cochrane Database of Systematic Reviews 2:CD000024Google Scholar
Saver, JL (2006). Time is brain-quantified. Stroke 37:263266CrossRefGoogle Scholar
Saver, JL, Jahan, R, Levy, EI et al. (2012). Solitaire flow restoration device versus the Merci Retriever in patients with acute ischemic stroke (SWIFT): A randomized, parallel-group, non-ineriority trial. Lancet 380:12411249CrossRefGoogle ScholarPubMed
Saver, JL, Goyal, M, Bonafe, A et al. (2015a). Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. New England Journal of Medicine 372:22852295CrossRefGoogle ScholarPubMed
Saver, JL, Starkman, S, Eckstein, M et al. (2015b). Prehospital use of magnesium sulfate as neuroprotection in acute stroke. New England Journal of Medicine 372:528536CrossRefGoogle ScholarPubMed
Smith, WS, Sung, G, Starkman, S et al. (2005). Safety and efficacy of mechanical embolectomy in acute ischemic: Results of the MERCI trial. Stroke 35:14321438CrossRefGoogle Scholar
Smith, WS, Sung, G, Saver, J et al. (2008). Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke 39:12051212CrossRefGoogle ScholarPubMed
Sussman, BJ, Fitch, TS (1958). Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 167:17051709CrossRefGoogle ScholarPubMed
Sutherland, BA, Minnerup, J, Balami, JS et al. (2012). Neuroprotection for ischemic stroke: Translation from the bench to the bedside. International Journal of Stroke 7:407418CrossRefGoogle Scholar
Tanswell, P, Modi, N, Combs, D et al. (2002). Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy in acute myocardial infarction. Clinical Pharmacokinetics 41:1229CrossRefGoogle ScholarPubMed
Tsivgoulis, G, Zand, R, Katsanos, AH et al. (2016). Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: A meta-analysis. JAMA Neurology 73:675683CrossRefGoogle ScholarPubMed
von Kummer, R, Mori, E, Truelsen, T et al. (2016). Desmoteplase 3 to 9 hours after major artery occlusion stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). Stroke 47:28802887CrossRefGoogle Scholar
Whiteley, WN, Emberson, JE, Lees, KR et al. (2016). Risk of intracerebral hemorrhage with alteplase after acute ischemic stroke: A secondary analysis of an individual patient data meta-analysis. Lancet Neurology 15:925933CrossRefGoogle ScholarPubMed
Wong, KS, Chen, C, Ng, PW et al. (2007). Low-molecular-weight heparin compared with aspirin for the treatment of acute ischemic stroke in Asian patients with large artery occlusive disease: A randomised study. Lancet Neurology 6:407413CrossRefGoogle ScholarPubMed
Yamaguchi, T, Mori, E, Minematsu, K et al. (2006). Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37:18101815CrossRefGoogle Scholar
Yang, MH, Lin, HY, Fu, J et al. (2015). Decompressive hemicraniectomy in patients with malignant middle cerebral artery infarction: A systematic review and meta-analysis. The Surgeon 13:230240CrossRefGoogle ScholarPubMed
Zivin, JA, Fisher, M, DeGirolami, U et al. (1985). Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230:12891292CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×